Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September
This article was originally published in The Pink Sheet Daily
Executive Summary
Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.
You may also be interested in...
Pargluva Fluid Retention, Cardiac Risk To Be Central Issues At Advisory Committee
Data showing heart failure rates with 5 mg dose of muraglitazar may be higher than with 30 mg pioglitazone (Lilly/Takeda's Actos) in type 2 diabetes patients will be presented to committee at Sept. 9 review.
Pargluva Fluid Retention, Cardiac Risk To Be Central Issues At Advisory Committee
Data showing heart failure rates with 5 mg dose of muraglitazar may be higher than with 30 mg pioglitazone (Lilly/Takeda's Actos) in type 2 diabetes patients will be presented to committee at Sept. 9 review.
Pfizer's Exubera Inhaled Insulin To Be Reviewed By Endocrine Committee Sept. 8
Inhalation powder will be evaluated for diabetes mellitus in adults by FDA's Endocrinologic & Metabolic Drugs Advisory Committee. Developed in conjunction with Sanofi-Aventis, Exubera would be first inhaled insulin product.